☸️SAIMSARA Journal
Online First Issues About Impressum

AI-Native Scoping Reviews & Evidence Mapping

ISSN 3054-3991 · ISSN record ↗
The Journal publishes machine-generated scoping reviews in medical and life sciences under human-editorial oversight, with transparent citations and versioning. Online First articles are continuously released by registered users. Issues are organized by domain and linked to an interactive AI RAG chatbot.
Editor's Choice papers are marked with .

Read aims & scope, publishing model & policies →

Issues

Domain issues provide a same-page filtered article view and a paired RAG agent.
Cardiac & Vascular Health icon
Cardiac & Vascular Health
Issue 1 • Vol 1 (2026) in progress
Longevity & Public Health icon
Longevity & Public Health
Issue 2 • Vol 1 (2026) in progress
Digital Health & Biotech icon
Digital Health & Biotech
Issue 3 • Vol 1 (2026) in progress
Mental & Neurological Health icon
Mental & Neurological Health
Issue 4 • Vol 1 (2026) in progress
Sports Medicine icon
Sports Medicine
Issue 5 • Vol 1 (2026) in progress
Pain Medicine icon
Pain Medicine
Issue 6 • Vol 1 (2026) in progress
Infectious Diseases icon
Infectious Diseases
Issue 7 • Vol 1 (2026) in progress
Skin & Aesthetics icon
Skin & Aesthetics
Issue 8 • Vol 1 (2026) in progress
Gastrointestinal & Metabolic Health icon
Gastrointestinal & Metabolic Health
Issue 9 • Vol 1 (2026) in progress
To propose a new domain issue or suggest curation criteria, use Impressum contact.
Online First: 205 article(s) • Page 6 / 18 Full archive (source) →
Skin & Aesthetics Skin & Aesthetics
Hair transplantation is no longer a simple choice between FUE and FUT, but a patient-specific technical workflow shaped by donor reserve, graft handling, recipient-site geometry, anesthesia, regenerative adjuncts, and reconstructive goals. This evidence map helps readers see which techniques are supported by original data, where survival and satisfaction signals are strongest, and where the field still needs better comparative trials.
Updated: 2026-05-23 • ID: hair-transplant-technique-20260518-170229-f9980b7c
Longevity & Public Health Longevity & Public Health
Transgender fertility care is not a niche issue but a recurring clinical gap: many TGD people want future parenthood, yet fertility preservation remains limited by cost, dysphoria, delayed counseling, and uneven access. The full evidence map helps readers see where fertility potential is preserved, where hormone effects remain uncertain, and how counseling, tissue/gamete preservation, ART, and inclusive care pathways should be clinically structured.
Updated: 2026-05-23 • ID: transgender-fertility-20260518-170020-ea868144
Digital Health & Biotech Digital Health & Biotech
EMA approval is not the end of evidence generation, but the start of a lifecycle in which uncertainty must be resolved through post-authorization studies, pharmacovigilance, RWE, and reimbursement reassessment. This evidence map shows where regulatory access, conditional authorization, surrogate endpoints, safety monitoring, and real-world confirmation succeed — and where they still leave clinicians, payers, and patients with critical unanswered questions.
Updated: 2026-05-23 • ID: european-medicines-agency-certification-20260517-175117-9a30a35e • Editorial check 2026-05-23
Digital Health & Biotech Digital Health & Biotech
FDA approval is not always the end of uncertainty — this evidence map shows how surrogate endpoints, accelerated pathways, thin pivotal trials, underrepresented populations, and delayed confirmatory evidence can leave major clinical questions unresolved after approval. The full evidence map helps clinicians, researchers, and policy-minded readers distinguish regulatory authorization from proven real-world benefit, safety, equity, and patient-centered value.
Updated: 2026-05-22 • ID: fda-approval-pitfalls-20260517-174500-e25de34b • Editorial check 2026-05-22
Skin & Aesthetics Skin & Aesthetics
Surgical loupes are not just magnifying glasses — they are practical visualization tools for microsurgery, aesthetic precision, reconstruction, dental procedures, and surgeon ergonomics. This evidence map shows where loupes can match microscopes, where they improve workflow, and where advanced visualization remains necessary.
Updated: 2026-05-22 • ID: surgical-loupes-20260517-154729-3d02cfe3 • Editorial check 2026-05-22
Sports Medicine Sports Medicine
This review maps 29 original studies comparing barefoot, minimalist, mobility, and conventional footwear across gait biomechanics, foot morphology, stability, knee loading, and performance. It shows where barefoot-like footwear may be useful — fall-risk stability, intrinsic foot strength, and knee OA load reduction — and where conventional shoes still matter, especially for impact moderation and postoperative walking capacity.
Updated: 2026-05-22 • ID: barefoot-conventional-shoes-20260429-204053-8b5ecae1 • Editorial check 2026-05-22
Mental & Neurological Health Mental & Neurological Health
Neuroleptic side effects are not only an EPS problem: the evidence map shows how motor toxicity, metabolic burden, endocrine disruption, sedation, autonomic effects, and patient-reported distress shift across drug classes and vulnerable populations. The full evidence map helps clinicians and researchers see where antipsychotics reduce risk, where they simply move toxicity into another domain, and why structured side-effect monitoring is essential in real-world care.
Updated: 2026-05-22 • ID: side-effects-neuroleptics-20260516-233742-690dd0a7 • Editorial check 2026-05-22
Digital Health & Biotech Digital Health & Biotech
AI can already imitate parts of executive work — drafting CEO-style messages, supporting decisions, and simulating crisis responses — but the evidence shows that authority, trust, ethics, and accountability still remain deeply human problems. The full SAIMSARA evidence map reveals where AI may genuinely augment leadership, where it becomes symbolic hype, and why the future CEO is more likely to be human-with-AI than AI-alone.
Updated: 2026-05-21 • ID: ai-ceo-20260516-202454-72fed8ad • Editorial check 2026-05-21
Pain Medicine Pain Medicine
Spinal cord stimulation is not simply an implant for chronic pain — it is a long-term neuromodulation pathway where benefit depends on careful selection, anatomy-aware implantation, psychosocial screening, and active device management. The full paper maps 270 references across 631 original studies to show where SCS is strongest, where complications cluster, and which patients may gain durable value rather than repeated revision or explantation.
Updated: 2026-05-21 • ID: spinal-cord-stimulator-20260515-234426-8a90f9b4 • Editorial check 2026-05-21
Cardiac & Vascular Health Cardiac & Vascular Health
Vascular closure devices are not simply tools to close a puncture site — they are workflow-enabling technologies whose value depends on anatomy, sheath size, imaging guidance, device selection, and bailout readiness. The full evidence map shows where VCDs accelerate hemostasis, ambulation, and discharge, and where complications cluster across femoral, large-bore, venous, TAVR, EVAR, ECMO, PCI, and electrophysiology settings.
Updated: 2026-05-21 • ID: vascular-closure-device-20260516-195936-7e1ad38d • Editorial check 2026-05-21
Cardiac & Vascular Health Cardiac & Vascular Health
Impella is not a simple “more support means better outcome” device: across 194 references and 432 original studies, the evidence shows a constant trade-off between ventricular unloading, survival signals, and complications such as bleeding, hemolysis, thrombocytopenia, vascular injury, and acquired von Willebrand syndrome. The full ☸️SAIMSARA evidence map shows where Impella appears strongest — early AMI-cardiogenic shock support, high-risk PCI, bridge-to-transplant/LVAD pathways, and selected RV failure scenarios — and where the evidence remains fragile, observational, or safety-limited.
Updated: 2026-05-20 • ID: impella-device-20260515-184929-7f98a528
Mental & Neurological Health Mental & Neurological Health
Alcohol and depression are not a simple “alcohol causes depression” story: across 185 references and 3,711 original studies, the evidence separates moderate-use signals from the consistent harms of heavy drinking, AUD, coping-motivated use, suicidality, relapse, and mortality. The full ☸️SAIMSARA evidence map gives a reference-linked view of where causality remains uncertain, which mechanisms matter clinically, and why integrated screening and treatment are needed instead of treating alcohol and depression as separate problems.
Updated: 2026-05-20 • ID: alcohol-depression-20260515-184039-2d680d6d
© 2026 SAIMSARA Journal • Impressum • Published by ML in Health Science GbR